ArticleNature2022
APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 321 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
321citing papers in PubMed, 3 pooled it
53.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
321 citing papers in PubMed, 3 syntheses or guidelines pooled it, 472 citations in OpenAlex.
- Apolipoprotein E Alleles Across the Spectrum of Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- The role of APOE ε4 in modulating the relationship between non-genetic risk factors and dementia: a system review and meta-analysis.Journal of neurology · 2025Pooled it
- Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Pooled it
- CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial.EBioMedicine · 2026Trial
- Overcoming the blood‒brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease.Drug delivery · 2026Review
- Early oligodendrocyte dysfunction signature in Alzheimer's disease: Insights from DNA methylomics and transcriptomics.Molecular psychiatry · 2026Article
- Review
- OSBPL6 protects against demyelination and behavioral disorder via promoting cholesterol transport in oligodendrocyte.Journal of advanced research · 2026Article
- Ovarian somatic tissue rejuvenates circulating apolipoproteins and promotes cognitive health in postreproductive female mice.GeroScience · 2026Article
- Genetic Modifiers of ABCA1 Activity Interact with APOE Isoforms to Mediate Alzheimer's Disease Risk.Annals of neurology · 2026Article
- Cell-based polygenic risk scores predict clinical progression and prioritize network-based therapeutic targets in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Distinct cellular phenotypes of language and executive decline in amyotrophic lateral sclerosis.Cell · 2026Article
- Review
- Mitochondria-Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential.Advanced healthcare materials · 2026Review
- Review
- Review
- Regional juxtacortical microstructural changes and gene expression provide insights into neurodegeneration in Alzheimer's disease.Translational psychiatry · 2026Article
- Neuroinflammation in Alzheimer's and Parkinson's diseases: pathogenic mechanisms and therapeutic strategies.Translational neurodegeneration · 2026Review
- From astrocyte cholesterol synthesis to synaptic dysfunction: mechanisms of neuron-glia lipid coupling.Molecular biology reports · 2026Review
- Sequential associations of myelin dysfunction with Aβ and Tau pathology in Alzheimer's disease: a dynamic myelin perturbation.Alzheimer's research & therapy · 2026Article
261 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
28 authors at 8 institutions in 2 countries.
Joel W Blanchard *Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Leyla Anne Akay *Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5944-2466
Jose Davila-Velderrain *MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0271-6267
Djuna von Maydell *Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Hansruedi MathysPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Shawn M DavidsonLewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.ORCID http://orcid.org/0000-0002-3475-0382
Audrey EffenbergerPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2405-2166
Chih-Yu ChenDepartment of Medicine, Emory Integrated Metabolomics and Lipidomics Core, Emory University School of Medicine, Atlanta, GA, USA.
Kristal Maner-SmithDepartment of Medicine, Emory Integrated Metabolomics and Lipidomics Core, Emory University School of Medicine, Atlanta, GA, USA.
Ihab HajjarDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Eric A OrtlundDepartment of Medicine, Emory Integrated Metabolomics and Lipidomics Core, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8855-3029
Michael BulaPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Emre AgbasPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ayesha NgPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Xueqiao JiangPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Martin KahnPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Cristina Blanco-DuquePicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nicolas LavoiePicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Liwang LiuPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ricardo ReyesNash Family Department of Neuroscience, Black Family Stem Cell Institute, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mt Sinai, New York, NY, USA.
Yuan-Ta LinPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Tak KoPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Lea R'BiboNash Family Department of Neuroscience, Black Family Stem Cell Institute, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mt Sinai, New York, NY, USA.
William T RalveniusPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Hugh P CamPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Manolis KellisMIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA. manoli@mit.edu.ORCID http://orcid.org/0000-0001-7113-9630
Li-Huei TsaiPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA. lhtsai@mit.edu.ORCID http://orcid.org/0000-0003-1262-0592
Massachusetts Institute of Technology · USEmory University · USAllen Institute for Brain Science · USBroad Institute · USHuman Technopole · ITPrinceton University · USRush University Medical Center · USUniversity of Pittsburgh · US
Funding
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BARNES, LISA L · 1991 to 2020
$49.1MEPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3MRush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7MRISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4MMulti-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7MPathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6MThere and Back Again: Epigenetic Reinforcement of Cellular Signaling States - OverallU54HG008097 · NHGRI · BROAD INSTITUTE, INC. · PI JAFFE, JACOB DAVID · 2014 to 2019
$9.3MEpigenomic, transcriptional and cellular dissection of Alzheimer's variantsR01AG058002 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HYMAN, BRADLEY T., JAENISCH, RUDOLF · 2017 to 2021
$7.9MThe role of the renin-angiotensin-endothelial pathway in ADRF1AG051633 · NIA · EMORY UNIVERSITY · PI HAJJAR, IHAB M, QUYYUMI, ARSHED A · 2015 to 2017
$6.0MSingle-cell transcriptional and epigenomic dissection of Alzheimer's Disease and Related DementiasU01NS110453 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KELLIS, MANOLIS, TSAI, LI-HUEI · 2018 to 2020
$4.0MCell type specific epigenetic analysis to understand complex mechanisms underlying Alzheimer's disease phenotypesRF1AG054012 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KELLIS, MANOLIS, TSAI, LI-HUEI · 2016 to 2016
$3.9MDissection of endosomal trafficking mechanisms in Alzheimer's DiseaseRF1AG062377 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TSAI, LI-HUEI · 2018 to 2018
$3.6MNHGRI NIH HHS U54 HG008097NIA NIH HHS K24 AG062786NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG058002NIA NIH HHS RF1 AG051633NIA NIH HHS RF1 AG054012NIA NIH HHS RF1 AG057470NIA NIH HHS RF1 AG062377NIA NIH HHS U01 AG046152NIA NIH HHS U01 AG061356NINDS NIH HHS R01 NS114239NINDS NIH HHS U01 NS110453NINDS NIH HHS UG3 NS115064NINDS NIH HHS UH3 NS115064
Abstract
APOE4 is the strongest genetic risk factor for Alzheimer's disease
Indexed as
Apolipoprotein E4BrainCholesterolNerve Fibers, MyelinatedOligodendrogliaAgingAlzheimer DiseaseAnimalsAutopsyBiological TransportGene Expression ProfilingHeterozygoteHomeostasisHumansInduced Pluripotent Stem CellsMemoryApolipoprotein E4Cholesterol
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.